Ritlecitinib

Ritlecitinib is a JAK inhibitor and selectively inhibits Janus kinase 3 (JAK3) and tyrosine kinase. Approved on the market in Germany since November 2023. The European Commission has approved ritlecitinib (^Litfulo®) for the treatment of severe alopecia areata in adults and adolescents aged 12 and over. However, German health insurance companies do not cover the costs of this approved preparation: Section 34 SGB V excludes the assumption of costs for drugs to improve hair growth.

1 hard capsule per day. Check platelets and lymphocytes before starting therapy and after 4 weeks.

Discontinue therapy if the absolute lymphocyte count is less than 0.5 × ^103/mm3, discontinue if the platelet count is less than 50 × ^103/mm3

Discontinue therapy in case of infections.

1. https://www.ema.europa.eu/en/medicines/human/EPAR/litfulo
2. https://labeling.pfizer.com/ShowLabeling.aspx?id=19915